Previous 10 | Next 10 |
- VBI and Syneos Health partner to prepare for commercial launch of VBI’s 3-antigen hepatitis B vaccine in the U.S., Europe, and Canada, pending regulatory approvals - Syneos Health selected for their robust and innovative commercialization experience and deep vaccine expertise...
Syneos Health ([[SYNH]] -5.0%) enters a strategic collaboration with ConcertAI to accelerate and streamline the implementation of novel oncology clinical trial research and study designs.“With COVID-19 delaying oncology trials, it’s critical that we look to delive...
BOSTON and MORRISVILLE, N.C., Dec. 03, 2020 (GLOBE NEWSWIRE) -- Syneos Health (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization and ConcertAI, the leader in oncology real world evidence (RWE) and patient outcomes solutions for the biopharmaceutical and health...
Syneos Health ([[SYNH]] -6.3%) has priced the previously announced underwritten secondary offering by Thomas H. Lee Partners and Advent International of 6M shares, at $61.90/shareThe offering is expected to close by December 3. For further details see: Syneos Health prices secondar...
Syneos Health (SYNH) has commenced an underwritten secondary offering by Thomas H. Lee Partners and Advent International of 6M shares of the Company’s common stock.The company is not selling any shares and will not receive any proceeds. For further details see: Thomas H. Lee...
Relief Therapeutics has a found a new use for Vasoactive Intestinal Peptide by repackaging it as RLF-100 (Aviptadil) to now fight COVID. RLF-100 is still undergoing clinical Phase 2/3 trials but has already shown promising use in an emergency setup for critically ill patients. In ...
MORRISVILLE, N.C., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (Nasdaq: SYNH) (the “Company” or “Syneos Health”), the only fully integrated biopharmaceutical solutions organization combining a CRO (Contract Research Organization) and a CCO (Contract Com...
Syneos Health (SYNH) has priced upsized offering of $600M (from $500M) of 3.625% senior unsecured notes due 2029 at par value.Closing date is November 24. Net proceeds will be used for general corporate purposes. The company also intends to amend its existing senior secured credit facilities ...
MORRISVILLE, N.C., Nov. 18, 2020 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (Nasdaq: SYNH) (the “Company” or “Syneos Health”), the only fully integrated biopharmaceutical solutions organization combining a CRO (Contract Research Organization) and a CCO (Contract Com...
Syneos Health (SYNH) to issue $500M of senior unsecured notes in a private offering. Net proceeds will be used for general corporate purposes. The company also intends to amend its existing senior secured credit facilities to extend the maturity date thereof to August 2024.Press release For...
News, Short Squeeze, Breakout and More Instantly...
Mitsubishi Tanabe Pharma America Celebrates Eight-Year Anniversary in the U.S. PR Newswire JERSEY CITY, N.J. , April 29, 2024 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) is celebrating its eight-year anniversary of being established in th...
Mitsubishi Tanabe Pharma America to Showcase Breadth of Neurodegenerative Research at 2024 American Academy of Neurology Annual Meeting PR Newswire Presentations span Parkinson's disease and ALS clinical and real-world evidence Oral platform sessions will highlight r...
Mitsubishi Tanabe Pharma America Receives U.S. Food and Drug Administration Orphan Drug Exclusivity for RADICAVA ORS® (edaravone) PR Newswire Orphan Drug Exclusivity recognized for RADICAVA ORS based on major contribution to patient care JERSEY CITY, N.J. ...